4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Non-Current Deffered Revenue of $2.1 million for Q1 2026, up 389.63% year-over-year from $434000.0 in Q1 2025, and up 185.23% quarter-over-quarter from $745000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Non-Current Deffered Revenue for 8 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue rose 389.63% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (up 389.63% YoY), while the FY2025 annual figure was $745000.0, down 29.52% from the prior year.
- Non-Current Deffered Revenue advanced to $2.1 million in Q1 2026 per FDMT's latest filing, from $745000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.1 million in Q1 2026 and bottomed at $219000.0 in Q2 2025.
- Historically, Non-Current Deffered Revenue has averaged $1.1 million across 5 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue plunged 84.94% — and 2026, when it surged 389.63%.
- 4D Molecular Therapeutics' Non-Current Deffered Revenue stood at $1.1 million in 2022, then dropped by 9.67% to $972000.0 in 2023, then rose by 8.74% to $1.1 million in 2024, then fell by 29.52% to $745000.0 in 2025, then jumped by 185.23% to $2.1 million in 2026.
- Business Quant data shows FDMT's Non-Current Deffered Revenue at $2.1 million in Q1 2026, $745000.0 in Q4 2025, and $835000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 2.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.96 Mn |
| Mar 31, 2026 | 2.13 Mn |
| Dec 31, 2025 | 745,000.00 |
| Sep 30, 2025 | 835,000.00 |
| Jun 30, 2025 | 219,000.00 |
| Mar 31, 2025 | 434,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 972,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 847,000.00 |
| Mar 31, 2023 | 884,000.00 |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.45 Mn |
| Mar 31, 2022 | 1.76 Mn |
| Dec 31, 2021 | 2.49 Mn |
| Sep 30, 2021 | 1.34 Mn |